Invention Grant
US08211427B2 EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart diseases
失效
EGLN2变体及其在预防或治疗血栓栓塞性疾病和冠心病中的用途
- Patent Title: EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart diseases
- Patent Title (中): EGLN2变体及其在预防或治疗血栓栓塞性疾病和冠心病中的用途
-
Application No.: US13015994Application Date: 2011-01-28
-
Publication No.: US08211427B2Publication Date: 2012-07-03
- Inventor: Detlef Kozian , Matthias Herrmann
- Applicant: Detlef Kozian , Matthias Herrmann
- Applicant Address: FR Paris
- Assignee: Sanofi-Aventis
- Current Assignee: Sanofi-Aventis
- Current Assignee Address: FR Paris
- Agent J. Darrell Fontenot
- Priority: DE102005048898 20051012
- Main IPC: A61K38/46
- IPC: A61K38/46 ; C12Q1/68 ; C40B30/06 ; C40B30/00
Abstract:
The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.
Public/Granted literature
Information query
IPC分类:
